CRF news

UCLH is the first site in the UK to recruit to an international vaccine study looking at the safety, tolerability and immune response generated by the Pfizer-BioNTech Covid-19 vaccine in healthy pregnant women.

A combination of two drugs could be an effective treatment for the debilitating disease lupus, according to preliminary evidence from a UCLH led trial.

UCLH is participating in the first Covid-19 vaccine study in the UK to recruit pregnant women.

UCLH is part of study announced by the Health Secretary in which volunteers will receive a third ‘booster’ Covid-19 vaccine.

Researchers at UCLH have begun a study which could set the foundations for how booster COVID-19 vaccinations are delivered in the future.

Volunteers are being asked to sign up to the latest Covid-19 vaccine study to begin across the UK including at UCLH.

The Com-Cov trial looking at alternating vaccines has been expanded to include the Moderna and Novavax vaccines in a new study.

A clinical trial of a new drug candidate for Alzheimer’s disease which has been developed at UCL in partnership with the pharmaceutical company Eisai is set to begin in the UK and US.

Researchers have begun a trial looking at whether a drug can slow progression of the devastating neurodegenerative condition Multiple System Atrophy (MSA).

UCLH has dosed the first UK participants in a study looking at alternating doses of different Covid-19 vaccines.

The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.

UCLH has welcomed the news that the Oxford-AstraZeneca coronavirus vaccine – which UCLH played a significant role in trialling – has today been approved for use in the UK.

UCLH researchers have recruited the first participant in the world to a study testing a long-acting antibody combination treatment to protect against Covid-19.

The Nursing Team at the NIHR UCLH Clinical Research Facility (CRF) have won the Contribution to World Class Research Award at the 2020 UCLH Celebrating Excellence Awards.

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its ‘Phase 3’ trials which involved UCLH that show its candidate vaccine is effective at preventing COVID-19 and offers a high level of protection.